JCXH-105 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Herpes Zoster (Shingles). According to GlobalData, Phase I drugs for Herpes Zoster (Shingles) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JCXH-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JCXH-105 overview

JCXH-105 is under development for the prevention of shingles (herpes zoster). The vaccine candidate is a self-replicating RNA (srRNA) vaccine encapsulated in lipid nanoparticle (LNP). It is administered through intramuscular route.

Immorna Hangzhou Biotechnology overview

Immorna Hangzhou Biotechnology (Immorna) is an healthcare service provider which focuses on research and development in the fields of oncology and focuses to offer other related services. Immorna is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of JCXH-105’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.